S. H. Swerdlow, E. Campo, and N. L. Harris, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol.2, 2008.

L. Arnaud, B. Hervier, and A. Néel, CNS involvement and treatment with interferon-a are independent prognostic factors in ErdheimChester disease: a multicenter survival analysis of 53 patients, Blood, vol.117, issue.10, pp.2778-2782, 2011.

G. Badalian-very, J. Vergilio, and B. A. Degar, Recurrent BRAF mutations in Langerhans cell histiocytosis, Blood, vol.116, issue.11, pp.1919-1923, 2010.

M. L. Berres, K. P. Lim, and T. Peters, BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups, J Exp Med, vol.211, issue.4, pp.669-683, 2014.

J. F. Emile, C. F. Amoura, Z. Haroche, and J. , BRAF mutations in Erdheim-Chester disease, J Clin Oncol, vol.31, issue.3, p.398, 2013.

J. Haroche, C. F. Arnaud, and L. , High prevalence of BRAF V600E mutations in ErdheimChester disease but not in other non-Langerhans cell histiocytoses, Blood, vol.120, issue.13, pp.2700-2703, 2012.

J. Haroche, F. Cohen-aubart, and E. , Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation, Blood, vol.121, issue.9, pp.1495-1500, 2013.

M. G. Cangi, R. Biavasco, and G. Cavalli, BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease, 2014.

, Ann Rheum Dis

D. S. Nelson, W. Quispel, and G. Badalian-very, Somatic activating ARAF mutations in Langerhans cell histiocytosis, Blood, vol.123, issue.20, pp.3152-3155, 2014.

E. L. Diamond, A. , O. Pentsova, and E. , Detection of an NRAS mutation in ErdheimChester disease, Blood, vol.122, issue.6, pp.1089-1091, 2013.

E. Colomba, Z. Hélias-rodzewicz, V. Deimling, and A. , Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing, J Mol Diagn, vol.15, issue.1, pp.94-100, 2013.

D. Michonneau, S. Kaltenbach, and C. Derrieux, BRAFV600E Mutation in a Histiocytic Sarcoma Arising From Hairy Cell Leukemia, 2014.

, J Clin Oncol

M. Arcila, C. Lau, K. Nafa, and M. Ladanyi, Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping, J Mol Diagn, vol.13, issue.1, pp.64-73, 2011.

F. Janku, J. J. Lee, and A. M. Tsimberidou, PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers, PLoS ONE, vol.6, issue.7, p.22769, 2011.

A. Klimek, V. M. Gaskell, and A. A. , Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF-and NRAS-mutant malignancies, Cancer Discov, vol.4, issue.5, pp.538-545, 2014.

P. A. Ascierto, D. Schadendorf, and C. Berking, MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study, Lancet Oncol, vol.14, issue.3, pp.249-256, 2013.

K. T. Flaherty, C. Robert, and P. Hersey, METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma, N Engl J Med, vol.367, issue.2, pp.107-114, 2012.

N. T. Ihle, R. Lemos, and P. Wipf, Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance, Cancer Res, vol.69, issue.1, pp.143-150, 2009.

F. Janku, D. S. Hong, and S. Fu, Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/ mTOR inhibitors, Cell Reports, vol.6, issue.2, pp.377-387, 2014.

R. Arceci, C. E. Allen, and I. Dunkel, Evaluation of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis, Blood, vol.122, p.2907, 2013.

A. Vaglio, D. Gianfreda, A. Federico, M. Galetti, M. Nicastro et al., Sirolimus plus prednisone for Erdheim-Chester disease: a pilot trial, Rheumatology Annual Meeting, p.789, 2013.